Cost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.contributorMinistério da Saúde-
Autor(es): dc.creatorde Almeida Cardoso, Marilia Mastrocolla-
Autor(es): dc.creatorMachado-Rugolo, Juliana-
Autor(es): dc.creatorLima, Silvana Andrea Molina-
Autor(es): dc.creatorde Andrade, Luis Gustavo Modelli-
Autor(es): dc.creatorda Silva Pereira Curado, Daniel-
Autor(es): dc.creatorPonce, Daniela-
Data de aceite: dc.date.accessioned2025-08-21T20:26:02Z-
Data de disponibilização: dc.date.available2025-08-21T20:26:02Z-
Data de envio: dc.date.issued2023-07-29-
Data de envio: dc.date.issued2023-07-29-
Data de envio: dc.date.issued2022-12-31-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1590/2175-8239-JBN-2022-0049en-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/248832-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/248832-
Descrição: dc.descriptionIntroduction: Hyperparathyroidism (SHPT) secondary to chronic kidney disease (CKD) is characterized by high levels of parathyroid hormone (PTH), hyperplasia of the parathyroid glands and cardiovascular disease. Selective and non-selective and selective vitamin D-receptor activators, calcimimetics, are available in the Brazilian market to reduce PTH levels. Objectives: To develop a cost-effectiveness (C/E) and budgetary impact (BI) analysis of intravenous paricalcitol vs. oral calcitriol for patients on dialysis with SHPT, from the perspective of the Brazilian Public Health Care System (SUS). Methodology: We built a decision-tree model to analyze C/E, which considered the outcome of avoided death and a time horizon of 1 year. As for the BI analysis, two scenarios were considered, one of demand and one of epidemiological approach, based on data from the Brazilian Society of Nephrology. Results: The analysis showed that the C/E ratio was R$ 1,213.68 per year, and an incremental effectiveness of 0.032, referring to avoided death. The incremental C/E ratio was R$37,927.50 per death averted by paricalcitol. It was estimated that the incremental BI with the expansion of paricalcitol use will be between R$1,600,202.28 and R$4,128,565.65 in the first year, considering the main and epidemiological scenarios. At the end of 5 years after the expansion of its use, an incremental BI was estimated between R$ 48,596,855.50 and R$ 62,90,555.73. Conclusion: Intravenous paricalcitol has superior efficacy and similar safety to oral calcitriol, reducing the overall mortality of dialysis patients, although it implies a higher cost.-
Descrição: dc.descriptionHospital das Clínicas da Faculdade de Medicina de Botucatu Departamento de Gestão de Atividades Acadêmicas Núcleo de Avaliação de Tecnologia em Saúde, SP-
Descrição: dc.descriptionMinistério da Saúde Departamento de Gestão e Incorporação de Tecnologias e Inovação em Saúde, DF-
Descrição: dc.descriptionHospital das Clínicas da Faculdade de Medicina de Botucatu Departamento de Gestão de Atividades Acadêmicas Núcleo de Avaliação de Tecnologia em Saúde, SP-
Formato: dc.format95-101-
Idioma: dc.languageen-
Relação: dc.relationJornal Brasileiro de Nefrologia-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectCalcitriol-
Palavras-chave: dc.subjectCost-Effectiveness Evaluation-
Palavras-chave: dc.subjectHyperparathyroidism, Secondary-
Palavras-chave: dc.subjectParicalcitol-
Palavras-chave: dc.subjectRenal Insufficiency, Chronic-
Título: dc.titleCost-effectiveness analysis of intravenous paricalcitol vs. oral calcitriol in the treatment of hyperparathyroidism secondary to chronic kidney disease-
Título: dc.titleAnálise de custo-efetividade do paricalcitol intravenoso vs. calcitriol oral no tratamento do hiperparatireoidismo secundário à doença renal crônica-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.